Trending Down-0.0421 (-10.9209%)
  • Bid / Lots
    0.3400/ 50
  • Ask / Lots
    0.3500/ 22
  • Open / Previous Close
    0.3998 / 0.3855
  • Day Range
    Low 0.3100
    High 0.3998
  • 52 Week Range
    Low 0.1320
    High 2.1400
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.3855
09:32 ET45250.3998
09:33 ET6000.39
09:35 ET12100.393
09:50 ET5000.3929
09:51 ET3750.3929
09:53 ET5000.3929
09:57 ET1470.3929
10:15 ET1000.3899
10:38 ET12830.383451
10:42 ET23000.3835
10:44 ET1200.3804
10:51 ET82000.3869
10:54 ET2000.3811
10:58 ET1000.3869
11:03 ET80000.380001
11:20 ET14640.3849
11:23 ET510510.3511
11:25 ET5000.3628
11:27 ET15000.3624
11:30 ET8140.3627
11:34 ET14570.368
11:39 ET14000.3601
11:50 ET2000.37
11:52 ET1000.3649
11:59 ET33780.360101
12:01 ET360910.346401
12:03 ET1000.347
12:06 ET10000.347
12:10 ET3000.347
12:12 ET86440.3643
12:15 ET1930.3643
12:19 ET3000.3578
12:35 ET3000.36
12:48 ET20000.360101
12:53 ET12650.3649
12:57 ET5000.3625
01:06 ET20000.364899
01:18 ET54830.36
01:20 ET43160.36
01:22 ET89520.36
01:27 ET1000.36
01:31 ET17270.3599
01:49 ET4000.359799
01:56 ET4060.3401
01:58 ET22560.3402
02:27 ET24000.34
02:34 ET1400.340101
02:48 ET2000.343
03:01 ET23720.34
03:26 ET7140.34
03:33 ET25010.34
03:39 ET63000.34
03:48 ET14000.3434
03:57 ET35000.3416
04:00 ET4000.3434
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPHGE
Biomx Inc
United StatesCING
Cingulate Inc
United StatesKTRA
Kintara Therapeutics Inc
United StatesKZIA
Kazia Therapeutics Ltd
United StatesONCR
Oncorus Inc
United StatesQNRX
Quoin Pharmaceuticals Ltd
As of 2023-02-07

Company Information

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Contact Information

22 Einstein St., Floor 5NESS-ZIONA, Israel 7414001


Independent Chairman of the Board
Russell Greig
Chief Executive Officer, Director
Jonathan Solomon
Chief Financial Officer
Marina Wolfson
Chief Development Officer
Merav Bassan
Chief Business Officer
Assaf Oron

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.